Peter S. Maclean
Research Subjects
Research Interests
Peter S. Maclean has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
A D Clark
Bone Marrow Transplant Unit, Glasgow Royal Infirmary, Scotland, UK
1 shared publicationA. M. Will
Haemophilia Comprehensive Care Centre Royal Manchester Children’s Hospital, Manchester
1 shared publication- Anne Parker
The Beatson, West of Scotland Cancer Centre, Glasgow, UK
1 shared publication - David Keeling
Oxford Haemophilia and Thrombosis Centre, Oxford University Hospitals, Churchill Hospital, Oxford, UK
1 shared publication - David Young
University of Strathclyde
1 shared publication E Farrell
Bone Marrow Transplant Unit, Glasgow Royal Infirmary, Scotland, UK
1 shared publication
Latest Publications
- 11 November 2010
- Published by Wiley in Haemophilia
- Vol. 17 (2) , 282-287
Treatment related factors and inhibitor development in children with severe haemophilia A
With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.
- 11 November 2010
- Published by Wiley in Haemophilia
- Vol. 17 (2) , 282-287
Treatment related factors and inhibitor development in children with severe haemophilia A
With the advent of modern factor replacement therapy the most important remaining obstacle to successful treatment in haemophilia A is the development of inhibitory antibodies against Facto VIII (FVIII). This retrospective case control study examined genetic variables and early treatment patterns in severe haemophilia A patients who subsequently developed clinically significant inhibitors to FVIII compared with matched controls who did not. Seventy eight inhibitor patients were identified from 13 UK centers over 25 years (1982-2007). For each case an age matched control was selected. Data on potential genetic and treatment related risk factors were collected for cases and controls. Treatment related data was collected for the first 50 exposure days (EDs) for controls or up to inhibitor development for cases. Risk factors were compared for significance by univariate and multivariate analysis. Of the genetic risk factors, major defects in the FVIII gene and non-caucasian ethnicity were each responsible for approximately 5-fold increases in inhibitor risk. When treatment related variables are considered, high intensity treatment increased inhibitor risk around 2.5 fold whether represented by the presence of peak treatment moments or by high overall treatment frequency. This finding was significant regardless of the timing of the high intensity treatment. Periods of intense treatment associated with surgery for porta-cath insertion were however not found to be associated with increased inhibitor risk. No association was shown between inhibitor development and age at first FVIII exposure, type of FVIII product, or the use of regular prophylaxis. This study confirms treatment-related factors as important risks for inhibitor development in Haemophilia A.
- 1 January 2007
- Published by Springer Nature in Drugs
- Vol. 67 (10) , 1429-1440
Hereditary and Acquired Antithrombin Deficiency
Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is growing...
- 1 January 2007
- Published by Springer Nature in Drugs
- Vol. 67 (10) , 1429-1440
Hereditary and Acquired Antithrombin Deficiency
Antithrombin is a glycoprotein critical to the regulation of coagulation. Its primary action is the inhibition of the activated coagulation factors IIa (thrombin) and Xa. In addition there is growing...